Bristol Myers Squibb’s Zeposia (ozanimod) Receives CHMP’s Positive Opinion for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Shots:

• The CHMP’s recommendation is based on P-III True North study evaluating Zeposia as an induction and maintenance therapy vs PBO in adult patients with moderately to severely active UC
• The study demonstrated improvements across all 1EPs and 2EPs including clinical remission, clinical response, endoscopic improvement and endoscopic histologic mucosal improvement @10 & 52wks.
• If approved by the EC, Zeposia will become the first and only oral sphingosine 1-phosphate (S1P) receptor modulator approved for UC in the EU

Click here to­ read full press release/ article | Ref: BMS | Image: BMS